Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMinireview

Protoporphyrin IX: the Good, the Bad, and the Ugly

Madhav Sachar, Karl E. Anderson and Xiaochao Ma
Journal of Pharmacology and Experimental Therapeutics February 2016, 356 (2) 267-275; DOI: https://doi.org/10.1124/jpet.115.228130
Madhav Sachar
Department of Pharmaceutical Sciences, Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (M.S., X.M.); and Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas (K.E.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl E. Anderson
Department of Pharmaceutical Sciences, Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (M.S., X.M.); and Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas (K.E.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaochao Ma
Department of Pharmaceutical Sciences, Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania (M.S., X.M.); and Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas (K.E.A.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Protoporphyrin IX (PPIX) is ubiquitously present in all living cells in small amounts as a precursor of heme. PPIX has some biologic functions of its own, and PPIX-based strategies have been used for cancer diagnosis and treatment (the good). PPIX serves as the substrate for ferrochelatase, the final enzyme in heme biosynthesis, and its homeostasis is tightly regulated during heme synthesis. Accumulation of PPIX in human porphyrias can cause skin photosensitivity, biliary stones, hepatobiliary damage, and even liver failure (the bad and the ugly). In this work, we review the mechanisms that are associated with the broad aspects of PPIX. Because PPIX is a hydrophobic molecule, its disposition is by hepatic rather than renal excretion. Large amounts of PPIX are toxic to the liver and can cause cholestatic liver injury. Application of PPIX in cancer diagnosis and treatment is based on its photodynamic effects.

Introduction

Protoporphyrin IX (PPIX) is a heterocyclic organic compound, which consists of four pyrrole rings, and is the final intermediate in the heme biosynthetic pathway. Its tetrapyrrole structure enables it to chelate transition metals to form metalloporphyrins, which perform a variety of biologic functions. Chelation of PPIX with iron forms heme (iron PPIX), which is a constituent of hemoproteins that play critical roles in oxygen transport, cellular oxidations and reductions, electron transport, and drug metabolism (Paoli et al., 2002; Kirton et al., 2005; Smith et al., 2010). Amounts of PPIX in cells actively synthesizing heme remain low under physiologic conditions, because the amount supplied does not exceed what is needed for heme synthesis. Thus, PPIX is efficiently converted to heme by the mitochondrial enzyme ferrochelatase (FECH), the final enzyme in the heme biosynthetic pathway. Inherited and acquired diseases and some xenobiotics can disturb heme synthesis and PPIX homeostasis, causing accumulation of PPIX in amounts that are sufficient to produce photosensitivity and liver damage (Magnus et al., 1961; Cox et al., 1998; Meerman, 2000; Chen et al., 2002; Dailey and Meissner, 2013). Clinically useful aspects of PPIX include its use for cancer diagnosis and therapy (Gold and Goldman, 2004; MacCormack, 2008). In this review, we discuss the broad aspects of PPIX, including its biosynthesis and regulation, its toxicity and clinical manifestations when present in excess, and its therapeutic applications.

PPIX Biosynthesis

Biosynthesis of heme is an eight-step process that occurs partly in mitochondria and partly in the cytoplasm (Fig. 1) (Ajioka et al., 2006). All eight enzymes in this pathway are encoded in the nucleus and are synthesized in the cytoplasm. PPIX is the final intermediate in the heme synthesis pathway. PPIX is formed by protoporphyrinogen oxidase (PPOX) and converted to heme by FECH, both of which are mitochondrial enzymes. Biosynthesis of heme initiates in the mitochondrial matrix where one molecule of glycine combines with one molecule of succinyl-CoA to form δ-aminolevulinic acid (ALA). This step is catalyzed by ALA synthase (ALAS; EC 2.3.1.37) in the presence of the cofactor pyridoxal phosphate (Koningsberger et al., 1995; Hunter and Ferreira, 2011). ALA formed in mitochondria is exported to the cytoplasm (Fig. 1). The mechanism of ALA transport is not fully understood, but a role for solute carrier family 25 member 38 and ATP-binding cassette subfamily B member (ABCB)10 has been suggested (Guernsey et al., 2009; Bayeva et al., 2013). Two molecules of ALA are condensed by ALA dehydratase (ALAD; EC 4.2.1.24, also known as porphobilinogen synthase) to form the monopyrrole porphobilinogen. Hydroxymethylbilane synthase (EC 2.5.1.61, also known as porphobilinogen deaminase) then assembles four molecules of porphobilinogen to form hydroxymethylbilane (Frydman and Feinstein, 1974). This reactive linear tetrapyrrole can spontaneously cyclize to form uroporphyrinogen I, which is not a heme precursor. The enzyme uroporphyrinogen synthase (EC 4.2.1.75) catalyzes hydroxymethylbilane ring closure with inversion of one of the pyrrole rings to form the heme precursor uroporphyrinogen III (Jordan and Shemin, 1973).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

PPIX/heme biosynthesis and disposition in mammalian cells. Multiple enzymes, cofactors, and transporters are involved in the pathway of PPIX/heme biosynthesis and in PPIX disposition. CPOX, coproporphyrinogen oxidase; FLVCR1, feline leukemia virus subgroup c receptor 1; HMBS, hydroxymethylbilane synthase; PLP, pyridoxal phosphate; SLC25A38, solute carrier family 25 member 38; UROD, uroporphyrinogen decarboxylase; UROS, uroporphyrinogen III synthase.

Uroporphyrinogen decarboxylase (EC 4.1.1.37) then removes carboxylic groups from the four acetic acid side chains of uroporphyrinogen III to form coproporphyrinogen III (Lewis and Wolfenden, 2008). This intermediate is then transported into mitochondria through ABCB6 (Krishnamurthy et al., 2006; Krishnamurthy and Schuetz, 2011), where it is decarboxylated to protoporphyrinogen IX by coproporphyrinogen oxidase (EC 1.3.3.3) (Proulx et al., 1993). Protoporphyrinogen IX is oxidized by PPOX (EC 1.3.3.4) with removal of six protons to form PPIX (Proulx et al., 1993). There are two major pathways for cellular PPIX disposition: synthesis of heme or excretion from the cell (Fig. 1). PPIX in most tissues is efficiently converted to heme by FECH (EC 4.99.1.1) in the presence of iron (Dailey, 1977). FECH activity is low in the oviduct of some birds, which allows PPIX to accumulate and serve as a brown pigment on eggshells (Schwartz et al., 1980). Mitoferrin 1 (MFRN1) and ABCB10 are involved in providing iron to mitochondria for heme synthesis (Shaw et al., 2006; Chen et al., 2009). In marrow reticulocytes, most PPIX remaining in small amounts after completion of heme and hemoglobin synthesis is chelated with zinc by FECH, and along with a smaller amount of metal-free PPIX is found in circulating erythrocytes. PPIX remaining in mitochondria may be transported into the extracellular space through ATP-binding cassette subfamily G member 2 (ABCG2) and peripheral benzodiazepine receptor (PBzR) (Jonker et al., 2002; Wendler et al., 2003; Solazzo et al., 2009; Kobuchi et al., 2012) (Fig. 1).

Regulation of PPIX Biosynthesis through ALAS

ALAS is the rate-limiting enzyme in PPIX production and heme synthesis. In mammals, ubiquitous and erythroid-specific forms of ALAS are encoded by separate genes on chromosomes 3 and X, respectively (Bishop et al., 1990). The ubiquitous form (ALAS1) is expressed in all tissues, including the liver. The erythroid-specific form (ALAS2) is only expressed in erythroid cells (Cox et al., 1990; Cotter et al., 1992). Although heme is synthesized in all cells, approximately 85% is produced in the bone marrow, and most of the rest in the liver. Heme is a key regulator of hepatic ALAS1 (Fig. 2). Heme directly binds to the upstream region of the ALAS1 gene and prevents its transcription (Sassa and Granick, 1970; Kolluri et al., 2005; Zheng et al., 2008). In addition, heme destabilizes ALAS1 mRNA and promotes degradation of mature ALAS1 protein (Cable et al., 2000; Roberts and Elder, 2001; Tian et al., 2011). Furthermore, heme prevents transport of the precursor of ALAS1 protein into mitochondria by binding to the terminal mitochondrial targeting sequence (Lathrop and Timko, 1993; Munakata et al., 2004; Dailey et al., 2005).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Regulation of PPIX homeostasis. Genetic factors and xenobiotics can disturb PPIX homeostasis through effects on (1) ALAS, (2) FECH, (3) iron supply, (4) PPIX transporters, (5) pyridoxal phosphate (PLP; the cofactor of ALAS), and (6) the enzymes and transporters downstream of ALAS and upstream of FECH.

In addition, ALAS1 is regulated by certain transcription factors and coactivators (Fig. 2). Fasting and feeding result in up- and downregulation of ALAS1 expression, respectively, by modulating the activity of proliferator-activated receptor-γ coactivator 1α (Giger and Meyer, 1981; Scassa et al., 1998; Varone et al., 1999; Wu et al., 1999; Handschin et al., 2005). Expression of proliferator-activated receptor-γ coactivator 1α is also regulated by a circadian oscillator Rev-erbα (Wu et al., 2009; Gerhart-Hines et al., 2013). Thus, ALAS1 expression is modulated by circadian rhythm. Most heme synthesized in the liver functions as a cofactor of cytochrome P450 enzymes (P450s), which are abundant in liver, turn over rapidly, and are critical for metabolism of many endogenous and exogenous chemicals. In response to P450 inducers, ALAS1 is upregulated by depletion of a regulatory heme pool in hepatocytes, and through nuclear receptors, such as the constitutive androstane receptor and the pregnane X receptor (Fraser et al., 2002, 2003; Podvinec et al., 2004). These receptors are important for regulation of both ALAS1 and P450s in the liver by drugs and other chemicals. Therefore, ligands of these nuclear receptors can upregulate ALAS1 expression and increase PPIX and heme synthesis (Fraser et al., 2003; Li et al., 2013).

Transcription of ALAS2, unlike ALAS1, is regulated by erythroid-specific transcription factors, such as GATA1 (Cable et al., 2000). Regarding the post-transcription of ALAS2, it is regulated by iron. ALAS2 mRNA possesses an iron regulatory element (IRE) in the 5′ untranslated region, which responds to cellular iron content (Bhasker et al., 1993; Melefors et al., 1993). In absence of iron, the iron-free form of iron regulatory protein (IRP) binds to the IRE, forming an IRE-IRP complex that prevents translation of ALAS2 (Wingert et al., 2005). This inhibitory effect of IRE-IRP complex is prevented by iron sulfur clusters (Napier et al., 2005; Rouault and Tong, 2005). These intricate regulatory mechanisms of ALAS2 by erythroid-specific transcription factors coordinate PPIX synthesis with iron supply, allowing efficient synthesis of large amounts of heme while avoiding an oversupply of either PPIX or iron, which would have adverse effects. Heme seems not to inhibit transcription of the ALAS2 or alter ALAS2 mRNA stability (Sadlon et al., 1999). However, heme may inhibit the translation of ALAS2 and the import of ALAS2 precursor into mitochondria (Lathrop and Timko, 1993; Smith and Cox, 1997).

Disregulation of PPIX Homeostasis

ALA Loading to Bypass ALAS1.

Because the rate-limiting step is bypassed, intermediates after ALA in the heme synthesis pathway accumulate, including PPIX. PPIX is a photosensitizer, and ALA administration can result in enough PPIX accumulation in lesions in the skin and other tissues to be the basis photodynamic therapy (Kennedy et al., 1990). Tissue selectivity is enhanced by direct application of ALA (e.g., to skin lesions) and by lesion-directed laser treatment. An ALA preparation is Food and Drug Administration approved for this purpose. ALA loading in humans also results in increased urinary excretion of coproporphyrin, particularly isomer III (Shimizu et al., 1978).

Gain of Function of ALAS2.

X-linked protoporphyria (XLP) is a recently characterized, rare X-linked disease due to gain-of-function mutations of ALAS2 (Whatley et al., 2008; Holme et al., 2009). These mutations alter the C-terminal portion of the ALAS2 gene (Whatley et al., 2008), which enhances the function of ALAS2 such that amounts of PPIX produced exceed that needed by FECH for heme synthesis. Increased metal-free PPIX in erythrocytes and plasma causes a painful, mostly nonblistering type of photosensitivity. Zinc PPIX, a product of normal FECH activity, is also increased in this condition, but mostly remains in circulating erythrocytes and is less photosensitizing.

Decreased ALAD Activity.

Deficient ALAD activity leads to accumulation of ALA and other intermediates, including PPIX, in large amounts in erythroid cells. This occurs in ALAD deficiency porphyria, the most rare human porphyria, causing elevations in ALA in plasma and urine, coproporphyrin III in urine (as in ALA loading), and zinc PPIX in erythrocytes. The same findings occur in lead poisoning, suggesting that increases in coproporphyrin III and erythrocyte PPIX in lead poisoning result largely from inhibition of ALAD and a resulting oversupply of ALA. In hereditary tyrosinemia type I, succinylacetone accumulates and potently inhibits ALAD, leading to similar biochemical findings and porphyria-like symptoms (Lindblad et al., 1977). Photosensitivity does not occur in these conditions, because the excess PPIX is predominantly zinc PPIX, reflecting adequate FECH activity. ALAD can also be inhibited by styrene in animals and humans (Fujita et al., 1987).

Decreased PPOX Activity.

This penultimate enzyme in the heme biosynthetic pathway catalyzes the oxidation of protoporphyrinogen IX to PPIX with loss of six protons. An inherited partial deficiency of PPOX in variegate porphyria (VP) causes hepatic accumulation of protoporphyinogen IX, which is then oxidized nonenzymatically to PPIX. Chronic, blistering photosensitivity is a common symptom in VP. Phenoxy acid herbicides are potent PPOX inhibitors, and cause PPIX accumulation and phototoxicity in exposed plants (Duke et al., 1990). These chemicals also inhibit PPOX and cause protoporphyrinogen IX and PPIX accumulation in rodent hepatocytes (Sinclair et al., 1994).

Decreased FECH Activity.

Loss-of-function FECH mutations are found in human erythropoietic protoporphyria (EPP) (Bonkowsky et al., 1975; Thapar and Bonkovsky, 2008). The FECH gene is located on the long arm of chromosome 18 on locus 18q21 (Whitcombe et al., 1991). More than 120 different FECH mutations have been identified in EPP (Thapar and Bonkovsky, 2008). Most commonly, a severe FECH mutation is inherited from one parent and a low expression (hypomorphic) FECH alteration that is common in the general population from the other parent (Gouya et al., 1999). FECH deficiency in EPP also impairs zinc PPIX formation, so the excess PPIX that accumulates is mostly metal-free (Nelson et al., 1998; Labbe et al., 1999).

Some xenobiotics and/or their metabolites inhibit FECH and cause PPIX accumulation. Salicylic acid, a nonsteroidal anti-inflammatory drug, binds directly to FECH and inhibits its activity, and can inhibit heme synthesis in cultured cells (Gupta et al., 2013). Certain xenobiotics require P450s to produce metabolites that are FECH inhibitors. 3,5-Diethoxycarbonyl-1,4-dihydrocollidine and the antifungal drug griseofulvin are examples of chemicals that are suicidal substrates of P450s, and their metabolism in mouse liver produces N-methyl- and N-ethyl-protoporphyrin IX, which are potent FECH inhibitors (Cole et al., 1981; Cole and Marks, 1984). These chemicals are also potent inducers of hepatic ALAS1, which further contributes to PPIX accumulation (Cole et al., 1981). Griseofulvin exacerbates acute hepatic porphyrias presumably by its inducing effect on ALAS1 and inhibition of FECH (Felsher and Redeker, 1967).

Decreased Iron Availability.

MFRN1 imports iron into mitochondria (Shaw et al., 2006), and a deficiency of MFRN1 reduces iron supply for FECH, limits heme synthesis, and leads to PPIX accumulation (Troadec et al., 2011). ABCB10 physically interacts with MFRN1 and increases the half-life of MFRN1 (Chen et al., 2009). Deficiency of ABCB10 impairs mitochondrial iron import and causes PPIX accumulation (Yamamoto et al., 2014). At the same time, ABCB10 deficiency in mice results in iron accumulation in cytoplasm and leads to sideroblastic anemia (Yamamoto et al., 2014).

Iron deficiency impairs heme formation because ferrous iron is a substrate for FECH. However, zinc can substitute for iron, so with iron deficiency FECH catalyzes an increase in formation of zinc PPIX (Braun, 1999), which accumulates in reticulocytes and is increased in circulating erythrocytes. An increase in erythrocyte zinc PPIX is an early indicator of iron deficiency and precedes the development of anemia (Labbe et al., 1999). Iron chelators can bind to ferrous iron in the cytoplasm of cells, such as hepatocytes, and prevent iron from entering mitochondria to reduce FECH function and cause PPIX accumulation (Amo et al., 2009; Blake and Curnow, 2010; Juzeniene et al., 2013). In rodent and chick embryo livers and isolated hepatocytes, iron chelation can limit heme synthesis sufficiently to potentiate induction of ALAS1 by drugs and steroids (Anderson et al., 1982). In lead and other heavy metal poisoning, disturbed iron hemostasis may account in part for zinc PPIX accumulation (Schauder et al., 2010). Impaired iron delivery to reticulocytes accounts in part for anemia of chronic disease, which is also associated with an increase in erythrocyte zinc PPIX (Braun, 1999).

PPIX Accumulation with Normal PPOX and FECH Activity and Iron Supply.

Amounts of zinc PPIX under normal and abnormal conditions are higher in younger than older erythrocytes, so increased erythropoiesis and shortened erythrocyte life span will increase the average concentration of PPIX. Therefore, an increase in zinc PPIX in erythrocytes is expected in any erythrocytic disorder (e.g., hemolytic anemias), even if heme synthetic enzymes and iron availability are not impaired (Anderson et al., 1977).

PPIX Transporters in PPIX Accumulation.

Excess PPIX synthesized in mitochondria needs to be pumped out to the cytoplasm and then to the extracellular space (Fig. 2). Transporters are required because the two carboxylate side chains of PPIX make the movement of PPIX across a lipid bilayer energetically unfavorable. PBzR locates in the outer membrane of mitochondria and its expression is increased during erythroid differentiation, suggesting that PBzR might be responsible for transporting PPIX (Pastorino et al., 1994; Taketani et al., 1994). Overexpression of recombinant PBzR in Escherichia coli supported the role of PBzR in PPIX movement (Wendler et al., 2003). Apart from PBzR, ABCG2 also contributes to PPIX movement (Jonker et al., 2002). ABCG2 is primarily localized on extracellular membranes and responsible for PPIX efflux (Solazzo et al., 2009). ABCG2 also locates in mitochondrial membranes and contributes to PPIX efflux from mitochondria (Kobuchi et al., 2012). ABCG2-deficient mice have a higher amount of PPIX in red blood cells, liver, and the Harderian gland than wild-type mice (Jonker et al., 2002, 2007).

In summary, PPIX homeostasis is maintained by close coordination of multiple factors, including ALAS, FECH, iron supply, and transporters of iron and PPIX (Fig. 2). These are the targets for genetic and environmentally induced disturbances in PPIX homeostasis. PPIX homeostasis can also be disturbed by alterations in enzymes, cofactors, and transporters downstream of ALAS and upstream of FECH (Fig. 2). For example, severe, homozygous, or compound heterozygous deficiency of any enzyme in the heme biosynthetic pathway after ALAS leads to an increase in erythrocyte PPIX, which is zinc chelated if FECH activity is preserved. Heme synthesis is increased in the marrow in an effort to compensate for the severe hemolytic anemia seen in some of these disorders.

Clinical Manifestations and Management of PPIX Toxicity

Normally there is little accumulation of PPIX or other intermediates in cells. Because the bone marrow and liver are most active in PPIX and heme synthesis, under abnormal conditions PPIX accumulation occurs either in the marrow and circulating erythrocytes or the liver (Smith, 1979; Bloomer, 1988; Ajioka et al., 2006; Anstey and Hift, 2007). During erythroid maturation when hemoglobin synthesis is active, excess PPIX can be chelated with zinc, or be pumped out to plasma through ABCG2 (Zhou et al., 2005). In EPP and XLP, metal-free PPIX originates from the marrow and circulating erythrocytes and is delivered to the skin and liver (Brancaleon et al., 2004; Desuzinges-Mandon et al., 2010).

PPIX-Mediated Skin Damage.

Metal-free PPIX is an endogenously produced photosensitizer. An acute, painful, and mostly nonblistering type of photosensitivity is the most common and significant clinical manifestation of increased metal-free PPIX in the protoporphyrias (EPP and XLP) (Thapar and Bonkovsky, 2008). To prevent symptoms, patients are forced to avoid light, which interferes with many professional and other everyday activities and impairs quality of life (Thapar and Bonkovsky, 2008). PPIX either in blood in the dermal vessels or after uptake into skin cells absorbs light energy and transfers this energy to oxygen, generating reactive oxygen species (ROS), which can lead to cytotoxicity through proteins, DNA, and lipid damage (Lim, 1989). These ROS can also cause local vasodilatation and edema by complement activation and mast cell degranulation (Baart de la Faille et al., 1991). Patients who remove themselves from exposure as soon as symptoms begin will recover quickly. Longer exposure can lead to more marked reactions with severe pain, redness, swelling, and even blistering, as well as systemic reactions, and may require several days or more for recovery (Dubrey et al., 2015). Repeated reactions to sunlight can have residual effects, such as waxy thickening of the skin, especially over the knuckles, hands, nose, and cheeks, and mild scarring (Horner et al., 2013). Because sunlight exposure is avoided, EPP and XLP patients are often vitamin D deficient (Wahlin et al., 2011a). Mild microcytic anemia with evidence of iron deficiency is common in EPP and XLP and is poorly understood (Holme et al., 2007), because elemental iron absorption is not impaired (Bossi et al., 2015).

Closely woven clothing, hats, and gloves are manufactured for patients with protoporphyria and other photosensitizing diseases. Pharmacological approaches have included pharmaceutical-grade β-carotene, narrow wave UVB phototherapy, cysteine, afamelanotide, antihistamines, and vitamin C (Table 1) (Sawyer et al., 1980; Krook and Haeger-Aronsen, 1982; Mathews-Roth et al., 1994; Collins and Ferguson, 1995; Warren and George, 1998; Wahlin et al., 2011a; Fabrikant et al., 2013; Tintle et al., 2014; Biolcati et al., 2015; Langendonk et al., 2015; Lengweiler et al., 2015; Minder and Schneider-Yin, 2015). Minder et al. (2009) reviewed the treatment options for dermal photosensitivity in EPP in 2009 and concluded that the data were insufficient to prove efficacy of any treatments studied in EPP. Since then, controlled trials have demonstrated improved light tolerance in EPP and XLP with afamelanotide, an α-melanocyte–stimulating hormone analog that increases skin melanogenesis (Harms et al., 2009; Fabrikant et al., 2013; Biolcati et al., 2015; Langendonk et al., 2015).

View this table:
  • View inline
  • View popup
TABLE 1

Pharmacological approaches for management of PPIX-mediated photosensitivity

PPIX-Mediated Hepatobiliary Disease.

Because PPIX concentrations in bile are high in EPP and XLP, PPIX-containing gallstones are common and may require cholecystectomy at an early age (Bloomer and Enriquez, 1982; Doss and Frank, 1989; Todd, 1991). PPIX-mediated liver damage, which occurs in less than 5% of patients with protoporphyria, is the most serious clinical manifestation and can be life threatening and require liver transplantation. The marrow is the major source of PPIX in EPP and XLP. Hepatic de novo synthesis is at best a minor contributor (Fig. 3). After uptake from plasma, hepatocytes transport PPIX into bile canuliculi. Bile is stored and concentrated in the gallbladder and delivered to the small intestine during meals, and some may be reabsorbed in the small intestine and delivered back to the liver by an enterohepatic circulation. This is the only route for excretion of PPIX because it is a large, hydrophobic molecule that cannot be excreted by the kidneys (Jonker et al., 2002, 2007).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Mechanisms of PPIX-mediated liver injury and strategies to manage this injury. PPIX-mediated hepatocyte and cholangiocyte damage initiates hepatobiliary injury in EPP. Approaches to manage this condition have included (1) suppression of PPIX biosynthesis by hemin; (2) plasmapheresis; (3) vitamin E or N-acetyl cysteine to reduce oxidative stress; (4) ursodeoxycholic acid to increase bile flow and PPIX excretion; (5) activated charcoal or cholestyramine to prevent reabsorption of PPIX from the small intestine; (6) liver transplantation; (7) bone marrow transplantation to restore FECH function; and in preclinical models (8) gene therapy targeting FECH.

Large amounts of PPIX are hepatotoxic, damaging both hepatocytes and cholangiocytes. PPIX impairs bile flow when administered in large amounts to bile fistula rodents (Lee et al., 1984). Once liver damage ensues, PPIX elimination by the liver is further compromised and levels of PPIX in plasma and erythrocytes can increase progressively, and bile composition becomes altered (Szechcinski et al., 1986; Meerman et al., 1999b). Increased delivery of PPIX to the liver can lead to further inflammation and accelerated damage to hepatocytes and cholangiocytes. Liver damage can progress slowly, as indicated by mild and often unexplained abnormal liver function tests, or advance rapidly to hepatic failure with evidence of both acute and chronic liver disease (Bruguera and Herrero, 2005; Anstey and Hift, 2007; Ma et al., 2010). Treatment with a combination of plasmapheresis to remove PPIX from plasma, hemin infusions to reduce marrow production of PPIX (Bloomer and Pierach, 1982; Gordeuk et al., 1986), cholestyramine (or activated charcoal) to interrupt the enterohepatic circulation of PPIX (Gorchein and Foster, 1999), bile acids such as ursodeoxycholic acid to enhance bile formation and flow (Van Hattum et al., 1986; Gross et al., 1998), and vitamin E to reduce oxidative stress (Komatsu et al., 2000; Singal et al., 2014) may achieve remission or slow the progression of liver disease and bridge the patient to hepatic transplantation. Such approaches are depicted in Fig. 3. These measures are not always effective and have not been applied in sufficient numbers of patients with hepatopathy to allow rigorous evaluation of efficiency (Anstey and Hift, 2007; Casanova-Gonzalez et al., 2010). New approaches to treatment and prevention of this severe complication of protoporphyria are needed.

Survival after liver transplantation for protoporphyric hepatopathy is comparable to that after other liver diseases (McGuire et al., 2005). However, because overproduction of PPIX by marrow continues, protoporphyric hepatopathy may recur (Samuel et al., 1988; de Torres et al., 1996; Meerman et al., 1999a; Dellon et al., 2002; McGuire et al., 2005). Marrow stem cell transplantation after a temporary remission of hepatopathy or liver transplantation can prevent recurrent liver damage (Rand et al., 2006; Wahlin and Harper, 2010; Dowman et al., 2011; Wahlin et al., 2011b; Singal et al., 2014). At present, identification in advance of patients at risk for development of hepatopathy is impossible. Motor neuropathy, which is characteristic of the acute porphyrias but not EPP and XLP, can develop in patients with severe protoporphyric hepatopathy, suggesting that PPIX or a product of PPIX may be neurotoxic under some conditions (Rank et al., 1993). Gene therapy targeting FECH, which is undergoing preclinical development, will, like bone marrow transplantation, restore FECH activity in the marrow (Poh-Fitzpatrick et al., 2002; Oustric et al., 2014).

PPIX-Based Strategies for Diagnosis and Therapy

PPIX can be activated by light to produce energy in the form of fluorescence and ROS. The photodynamic effect of hematoporphyrin, which is closely related to PPIX and formed by the acid hydrolysis of hemoglobin, was demonstrated in a self-experiment by Meyer-Betz (1913). After self-injection of hematoporphyrin, he developed severe swelling of the face and other sun-exposed areas, similar to the phototoxic reactions seen in EPP and XLP. Use of PPIX as a photosensitizer for photodynamic therapy was explored after observing photodynamic effects in erythrocytes of EPP patients containing excess amount of PPIX (Kosenow and Treibs, 1953; Kosenow, 1954). Administration of ALA, which is more stable and readily taken up in tissues in whole animals, leads to dose-related PPIX accumulation in varying amounts in different tissues (Anderson et al., 1981). Exogenous ALA bypasses the regulatory control of PPIX by ALAS during heme biosynthesis and results in PPIX accumulation. In 1990, ALA was administered locally to generate endogenous PPIX for photodynamic treatment of basal cell carcinomas (Kennedy et al., 1990). Afterward, endogenous PPIX-based strategies have been used for many clinical applications (Karu and Letokhov, 1994; Ishizuka et al., 2011; Rollakanti et al., 2013; Mordon, 2014). Thus, ALA can be administered orally or locally as a stable precursor for PPIX. PPIX-based therapy is now approved by the Food and Drug Administration for treatment of bronchial and esophageal cancers and early malignant lesions of the skin, bladder, breast, stomach, and oral cavity (Henderson and Dougherty, 1992; Pass, 1993; Oleinick and Evans, 1998; Dougherty, 2002; MacCormack, 2008).

Cancer cells accumulate a higher amount of PPIX than normal cells when treated with ALA (Fukuda et al., 1989). Photoactivation of PPIX in cancer cells generates ROS, which can cause apoptosis and necrosis by attacking mitochondrial and cytoplasmic proteins and destroying cell membrane integration (Mroz et al., 2011b; Mfouo-Tynga and Abrahamse, 2015). ROS generated from PPIX also damages blood vessels, leading to vascular occlusions, which deprives the tumor of oxygen and nutrients, thereby impairing tumor growth (Dougherty et al., 1998). ROS can also elicit an immune response that suppresses tumor growth (Castano et al., 2006; Garg et al., 2010; Mroz et al., 2010; Mroz et al., 2011a). Photodynamic effects of PPIX have also been used for cancer diagnosis. PPIX emits red fluorescence when irradiated with light at wave lengths of 400–410 nm, making cancerous lesions that have higher concentrations or less overlying epithelium than surrounding tissue more visible (Ishizuka et al., 2011).

In addition to cancer therapy and diagnosis, the photodynamic effects of endogenously generated PPIX have been used for the treatment of acne, sebaceous skin, rosacea, rhinophyma, Bowen’s disease, androgenic alopecia, cosmetic enhancement, and photo rejuvenations (Goldman and Kincad, 2002; Nestor et al., 2006). Furthermore, PPIX-based strategies have been explored against Gram-positive and -negative bacteria, parasites, yeasts, and fungi (Hamblin and Hasan, 2004; O'Riordan et al., 2005; Akilov et al., 2006; EN, 2006; Donnelly et al., 2008; Goslinski et al., 2008).

Conclusions

PPIX homeostasis can be disturbed by effects on enzymes in the heme biosynthetic pathway (e.g., ALAS, PPOX, and FECH), transporters of pathway intermediates, and iron supply. In EPP and XLP, which are caused by loss-of-function FECH mutations and gain-of-function ALAS2 mutations, respectively, PPIX accumulates initially in the marrow and causes painful cutaneous phototoxicity. Excess PPIX in VP is derived from accumulation of protoporphyrinogen IX, the immediate precursor of PPIX. PPIX is water insoluble, and its excretion occurs through the liver and biliary system. An excessive amount of PPIX presented to the liver in EPP and XLP can cause hepatobiliary injury and liver failure. The photodynamic effect of PPIX produced endogenously after ALA administration can be used for cancer diagnosis and treatment. Approaches for management of EPP and XLP are advancing with emphasis on light protection, such as the development of an α-melanocyte–stimulating hormone that increases skin melanogenesis. Novel therapies are needed to reduce endogenous PPIX levels in these conditions and to treat and prevent PPIX-mediated liver injury.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Sachar, Anderson, Ma.

Footnotes

    • Received July 27, 2015.
    • Accepted November 20, 2015.
  • This work was supported in part by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK090305].

  • dx.doi.org/10.1124/jpet.115.228130.

Abbreviations

ABCB
ATP-binding cassette subfamily B member
ABCG2
ATP-binding cassette subfamily G member 2
ALA
δ-aminolevulinic acid
ALAD
ALA dehydratase
ALAS
ALA synthase
ALAS1
the ubiquitous form of ALAS; ALAS2, the erythroid-specific form of ALAS
EPP
erythropoietic protoporphyria
FECH
ferrochelatase
IRE
iron regulatory element
IRP
iron regulatory protein
MFRN1
mitoferrin 1
PBzR
peripheral benzodiazepine receptor
PPIX
protoporphyrin IX
PPOX
protoporphyrinogen oxidase
ROS
reactive oxygen species
VP
variegate porphyria
XLP
X-linked protoporphyria
  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Ajioka RS,
    2. Phillips JD, and
    3. Kushner JP
    (2006) Biosynthesis of heme in mammals. Biochim Biophys Acta 1763:723–736.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Akilov OE,
    2. Kosaka S,
    3. O’Riordan K,
    4. Song X,
    5. Sherwood M,
    6. Flotte TJ,
    7. Foley JW, and
    8. Hasan T
    (2006) The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem Biol 13:839–847.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Amo
    T, Kawanishi N, Uchida M, Fujita H, Oyanagi E, Utsumi T, Ogino T, Inoue K, Shuin T, Utsumi K, and Sasaki J (2009) Mechanism of cell death by 5-aminolevulinic acid-based photodynamic action and its enhancement by ferrochelatase inhibitors in human histiocytic lymphoma cell line U937. Cell Biochem Funct 27:503–515.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Anderson KE,
    2. Drummond GS,
    3. Freddara U,
    4. Sardana MK, and
    5. Sassa S
    (1981) Porphyrogenic effects and induction of heme oxygenase in vivo by delta-aminolevulinic acid. Biochim Biophys Acta 676:289–299.
    OpenUrlPubMed
  5. ↵
    1. Anderson KE,
    2. Freddara U, and
    3. Kappas A
    (1982) Induction of hepatic cytochrome P-450 by natural steroids: relationship to the induction of δ-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 217:597–608.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Anderson KE,
    2. Sassa S,
    3. Peterson CM, and
    4. Kappas A
    (1977) Increased erythrocyte uroporphyrinogen-l-synthetase, δ-aminolevulinic acid dehydratase and protoporphyrin in hemolytic anemias. Am J Med 63:359–364.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Anstey AV and
    2. Hift RJ
    (2007) Liver disease in erythropoietic protoporphyria: insights and implications for management. Postgrad Med J 83:739–748.
    OpenUrlFREE Full Text
  8. ↵
    1. Baart de la Faille H,
    2. Bijlmer-Iest JC,
    3. van Hattum J,
    4. Koningsberger J,
    5. Rademakers LH, and
    6. van Weelden H
    (1991) Erythropoietic protoporphyria: clinical aspects with emphasis on the skin. Curr Probl Dermatol 20:123–134.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Bayeva M,
    2. Khechaduri A,
    3. Wu R,
    4. Burke MA,
    5. Wasserstrom JA,
    6. Singh N,
    7. Liesa M,
    8. Shirihai OS,
    9. Langer NB,
    10. Paw BH,
    11. et al.
    (2013) ATP-binding cassette B10 regulates early steps of heme synthesis. Circ Res 113:279–287.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Bhasker CR,
    2. Burgiel G,
    3. Neupert B,
    4. Emery-Goodman A,
    5. Kühn LC, and
    6. May BK
    (1993) The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control. J Biol Chem 268:12699–12705.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Biolcati G,
    2. Marchesini E,
    3. Sorge F,
    4. Barbieri L,
    5. Schneider-Yin X, and
    6. Minder EI
    (2015) Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol 172:1601–1612.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bishop DF,
    2. Henderson AS, and
    3. Astrin KH
    (1990) Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 7:207–214.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Blake E and
    2. Curnow A
    (2010) The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol 86:1154–1160.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Bloomer JR
    (1988) The liver in protoporphyria. Hepatology 8:402–407.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Bloomer JR and
    2. Enriquez R
    (1982) Evidence that hepatic crystalline deposits in a patient with protoporphyria are composed of protoporphyrin. Gastroenterology 82:569–573.
    OpenUrlPubMed
  16. ↵
    1. Bloomer JR and
    2. Pierach CA
    (1982) Effect of hematin administration to patients with protoporphyria and liver disease. Hepatology 2:817–821.
    OpenUrlCrossRefPubMed
    1. Boffa MJ,
    2. Ead RD,
    3. Reed P, and
    4. Weinkove C
    (1996) A double-blind, placebo-controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 12:27–30.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bonkowsky HL,
    2. Bloomer JR,
    3. Ebert PS, and
    4. Mahoney MJ
    (1975) Heme synthetase deficiency in human protoporphyria: demonstration of the defect in liver and cultured skin fibroblasts. J Clin Invest 56:1139–1148.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bossi K,
    2. Lee J,
    3. Schmeltzer P,
    4. Holburton E,
    5. Groseclose G,
    6. Besur S,
    7. Hwang S, and
    8. Bonkovsky HL
    (2015) Homeostasis of iron and hepcidin in erythropoietic protoporphyria. Eur J Clin Invest 45:1032–1041.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Brancaleon L,
    2. Magennis SW,
    3. Samuel ID,
    4. Namdas E,
    5. Lesar A, and
    6. Moseley H
    (2004) Characterization of the photoproducts of protoporphyrin IX bound to human serum albumin and immunoglobulin G. Biophys Chem 109:351–360.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Braun J
    (1999) Erythrocyte zinc protoporphyrin. Kidney Int Suppl 69:S57–S60.
    OpenUrlPubMed
  21. ↵
    1. Bruguera M and
    2. Herrero C
    (2005) [Liver disease in erythropoietic protoporphyria]. Gastroenterol Hepatol 28:632–636.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Cable EE,
    2. Miller TG, and
    3. Isom HC
    (2000) Regulation of heme metabolism in rat hepatocytes and hepatocyte cell lines: delta-aminolevulinic acid synthase and heme oxygenase are regulated by different heme-dependent mechanisms. Arch Biochem Biophys 384:280–295.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Casanova-González MJ,
    2. Trapero-Marugán M,
    3. Jones EA, and
    4. Moreno-Otero R
    (2010) Liver disease and erythropoietic protoporphyria: a concise review. World J Gastroenterol 16:4526–4531.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Castano AP,
    2. Mroz P, and
    3. Hamblin MR
    (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6:535–545.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Chen FP,
    2. Risheg H,
    3. Liu Y, and
    4. Bloomer J
    (2002) Ferrochelatase gene mutations in erythropoietic protoporphyria: focus on liver disease. Cell Mol Biol (Noisy-le-grand) 48:83–89.
    OpenUrlPubMed
  26. ↵
    1. Chen W,
    2. Paradkar PN,
    3. Li L,
    4. Pierce EL,
    5. Langer NB,
    6. Takahashi-Makise N,
    7. Hyde BB,
    8. Shirihai OS,
    9. Ward DM,
    10. Kaplan J,
    11. et al.
    (2009) Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci USA 106:16263–16268.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Cole SP and
    2. Marks GS
    (1984) Ferrochelatase and N-alkylated porphyrins. Mol Cell Biochem 64:127–137.
    OpenUrlPubMed
  28. ↵
    1. Cole SP,
    2. Zelt DT, and
    3. Marks GS
    (1981) Comparison of the effects of griseofulvin and 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on ferrochelatase activity in chick embryo liver. Mol Pharmacol 19:477–480.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Collins P and
    2. Ferguson J
    (1995) Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 132:956–963.
    OpenUrlPubMed
  30. ↵
    1. Cotter PD,
    2. Willard HF,
    3. Gorski JL, and
    4. Bishop DF
    (1992) Assignment of human erythroid delta-aminolevulinate synthase (ALAS2) to a distal subregion of band Xp11.21 by PCR analysis of somatic cell hybrids containing X; autosome translocations. Genomics 13:211–212.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Cox TC,
    2. Bawden MJ,
    3. Abraham NG,
    4. Bottomley SS,
    5. May BK,
    6. Baker E,
    7. Chen LZ, and
    8. Sutherland GR
    (1990) Erythroid 5-aminolevulinate synthase is located on the X chromosome. Am J Hum Genet 46:107–111.
    OpenUrlPubMed
  32. ↵
    1. Cox TM,
    2. Alexander GJ, and
    3. Sarkany RP
    (1998) Protoporphyria. Semin Liver Dis 18:85–93.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Dailey HA Jr.
    (1977) Purification and characterization of the membrane-bound ferrochelatase from Spirillum itersonii. J Bacteriol 132:302–307.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Dailey HA and
    2. Meissner PN
    (2013) Erythroid heme biosynthesis and its disorders. Cold Spring Harb Perspect Med 3:a011676.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Dailey TA,
    2. Woodruff JH, and
    3. Dailey HA
    (2005) Examination of mitochondrial protein targeting of haem synthetic enzymes: in vivo identification of three functional haem-responsive motifs in 5-aminolaevulinate synthase. Biochem J 386:381–386.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. de Torres I,
    2. Demetris AJ, and
    3. Randhawa PS
    (1996) Recurrent hepatic allograft injury in erythropoietic protoporphyria. Transplantation 61:1412–1413.
    OpenUrlPubMed
  37. ↵
    1. Dellon ES,
    2. Szczepiorkowski ZM,
    3. Dzik WH,
    4. Graeme-Cook F,
    5. Ades A,
    6. Bloomer JR,
    7. Cosimi AB, and
    8. Chung RT
    (2002) Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation 73:911–915.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Desuzinges-Mandon E,
    2. Arnaud O,
    3. Martinez L,
    4. Huché F,
    5. Di Pietro A, and
    6. Falson P
    (2010) ABCG2 transports and transfers heme to albumin through its large extracellular loop. J Biol Chem 285:33123–33133.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Donnelly RF,
    2. McCarron PA, and
    3. Tunney MM
    (2008) Antifungal photodynamic therapy. Microbiol Res 163:1–12.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Doss MO and
    2. Frank M
    (1989) Hepatobiliary implications and complications in protoporphyria, a 20-year study. Clin Biochem 22:223–229.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Dougherty TJ
    (2002) An update on photodynamic therapy applications. J Clin Laser Med Surg 20:3–7.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Dougherty TJ,
    2. Gomer CJ,
    3. Henderson BW,
    4. Jori G,
    5. Kessel D,
    6. Korbelik M,
    7. Moan J, and
    8. Peng Q
    (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Dowman JK,
    2. Gunson BK,
    3. Mirza DF,
    4. Badminton MN,
    5. Newsome PN, and
    6. UK Liver Selection and Allocation Working Party
    (2011) UK experience of liver transplantation for erythropoietic protoporphyria. J Inherit Metab Dis 34:539–545.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Dubrey SW,
    2. Ghonim S,
    3. Chehab O, and
    4. Patel K
    (2015) Extreme photosensitivity in a patient with erythropoietic protoporphyria. Br J Hosp Med 76:52–53.
    OpenUrlCrossRef
  45. ↵
    1. Duke SO,
    2. Becerrill JM,
    3. Sherman TD,
    4. Lydon J, and
    5. Matsumoto H
    (1990) The role of protoporphyrin IX in the mechanism of action of diphenyl ether herbicides. Pestic Sci 30:367–378.
    OpenUrlCrossRef
    1. Durantini EN
    (2006) Photodynamic inactivation of bacteria. Curr Bioact Compd 2:127–142.
    OpenUrlCrossRef
  46. ↵
    1. Fabrikant J,
    2. Touloei K, and
    3. Brown SM
    (2013) A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol 12:775–779.
    OpenUrlPubMed
  47. ↵
    1. Felsher BF and
    2. Redeker AG
    (1967) Acute intermittent porphyria: effect of diet and griseofulvin. Medicine 46:217–223.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Fraser DJ,
    2. Podvinec M,
    3. Kaufmann MR, and
    4. Meyer UA
    (2002) Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem 277:34717–34726.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Fraser DJ,
    2. Zumsteg A, and
    3. Meyer UA
    (2003) Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J Biol Chem 278:39392–39401.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Frydman RB and
    2. Feinstein G
    (1974) Studies on porphobilinogen deaminase and uroporphyrinogen 3 cosynthase from human erythrocytes. Biochim Biophys Acta 350:358–373.
    OpenUrlPubMed
  51. ↵
    1. Fujita H,
    2. Koizumi A,
    3. Furusawa T, and
    4. Ikeda M
    (1987) Decreased erythrocyte delta-aminolevulinate dehydratase activity after styrene exposure. Biochem Pharmacol 36:711–716.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Fukuda H,
    2. Paredes S, and
    3. Batlle AM
    (1989) Tumor-localizing properties of porphyrins: in vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms. Drug Deliv 5:133–139.
    OpenUrl
  53. ↵
    1. Garg AD,
    2. Nowis D,
    3. Golab J, and
    4. Agostinis P
    (2010) Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 15:1050–1071.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Gerhart-Hines Z,
    2. Feng D,
    3. Emmett MJ,
    4. Everett LJ,
    5. Loro E,
    6. Briggs ER,
    7. Bugge A,
    8. Hou C,
    9. Ferrara C,
    10. Seale P,
    11. et al.
    (2013) The nuclear receptor Rev-erbα controls circadian thermogenic plasticity. Nature 503:410–413.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Giger U and
    2. Meyer UA
    (1981) Induction of delta-aminolevulinate synthase and cytochrome P-450 hemoproteins in hepatocyte culture: effect of glucose and hormones. J Biol Chem 256:11182–11190.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Gold MH and Goldman MP (2004) 5-aminolevulinic acid photodynamic therapy: where we have been and where we are going. Dermatol Surg 30:1077-1083; discussion 1083-1074.
  57. ↵
    Goldman MP, Atkin D, and Kincad S (2002) PDT/ALA in the treatment of actinic damage: real world experience. J Lasers Surg Med 14(s):24.
  58. ↵
    1. Gorchein A and
    2. Foster GR
    (1999) Liver failure in protoporphyria: long-term treatment with oral charcoal. Hepatology 29:995–996.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Gordeuk VR,
    2. Brittenham GM,
    3. Hawkins CW,
    4. Mukhtar H, and
    5. Bickers DR
    (1986) Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. Ann Intern Med 105:27–31.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Goslinski TKK,
    2. Piskorz J,
    3. Kryjewski M,
    4. Wierzehowski M, and
    5. Sobiak S
    (2008) Prospects for photodynamic antimicrobial chemotherapy—PACT. Postepy Mikrobiologii 47:447–456.
    OpenUrl
  61. ↵
    1. Gouya L,
    2. Puy H,
    3. Lamoril J,
    4. Da Silva V,
    5. Grandchamp B,
    6. Nordmann Y, and
    7. Deybach JC
    (1999) Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 93:2105–2110.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Gross U,
    2. Frank M, and
    3. Doss MO
    (1998) Hepatic complications of erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 14:52–57.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Guernsey DL,
    2. Jiang H,
    3. Campagna DR,
    4. Evans SC,
    5. Ferguson M,
    6. Kellogg MD,
    7. Lachance M,
    8. Matsuoka M,
    9. Nightingale M,
    10. Rideout A,
    11. et al.
    (2009) Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 41:651–653.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Gupta V,
    2. Liu S,
    3. Ando H,
    4. Ishii R,
    5. Tateno S,
    6. Kaneko Y,
    7. Yugami M,
    8. Sakamoto S,
    9. Yamaguchi Y,
    10. Nureki O,
    11. et al.
    (2013) Salicylic acid induces mitochondrial injury by inhibiting ferrochelatase heme biosynthesis activity. Mol Pharmacol 84:824–833.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Hamblin MR and
    2. Hasan T
    (2004) Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 3:436–450.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Handschin C,
    2. Lin J,
    3. Rhee J,
    4. Peyer AK,
    5. Chin S,
    6. Wu PH,
    7. Meyer UA, and
    8. Spiegelman BM
    (2005) Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505–515.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Harms J,
    2. Lautenschlager S,
    3. Minder CE, and
    4. Minder EI
    (2009) An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 360:306–307.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Henderson BW and
    2. Dougherty TJ
    (1992) How does photodynamic therapy work? Photochem Photobiol 55:145–157.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Holme SA,
    2. Whatley SD,
    3. Roberts AG,
    4. Anstey AV,
    5. Elder GH,
    6. Ead RD,
    7. Stewart MF,
    8. Farr PM,
    9. Lewis HM,
    10. Davies N,
    11. et al.
    (2009) Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol 129:599–605.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Holme SA,
    2. Worwood M,
    3. Anstey AV,
    4. Elder GH, and
    5. Badminton MN
    (2007) Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 110:4108–4110.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Horner ME,
    2. Alikhan A,
    3. Tintle S,
    4. Tortorelli S,
    5. Davis DM, and
    6. Hand JL
    (2013) Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol 52:1464–1480.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Hunter GA and
    2. Ferreira GC
    (2011) Molecular enzymology of 5-aminolevulinate synthase, the gatekeeper of heme biosynthesis. Biochim Biophys Acta 1814:1467–1473.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Ishizuka M,
    2. Abe F,
    3. Sano Y,
    4. Takahashi K,
    5. Inoue K,
    6. Nakajima M,
    7. Kohda T,
    8. Komatsu N,
    9. Ogura S, and
    10. Tanaka T
    (2011) Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol 11:358–365.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Jonker JW,
    2. Buitelaar M,
    3. Wagenaar E,
    4. Van Der Valk MA,
    5. Scheffer GL,
    6. Scheper RJ,
    7. Plosch T,
    8. Kuipers F,
    9. Elferink RP,
    10. Rosing H,
    11. et al.
    (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649–15654.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Jonker JW,
    2. Musters S,
    3. Vlaming ML,
    4. Plösch T,
    5. Gooijert KE,
    6. Hillebrand MJ,
    7. Rosing H,
    8. Beijnen JH,
    9. Verkade HJ, and
    10. Schinkel AH
    (2007) Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. Am J Physiol Cell Physiol 292:C2204–C2212.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. Jordan PM and
    2. Shemin D
    (1973) Purification and properties of uroporphyrinogen I synthetase from Rhodopseudomonas spheroides. J Biol Chem 248:1019–1024.
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Juzeniene A,
    2. Iani V, and
    3. Moan J
    (2013) Clearance mechanism of protoporphyrin IX from mouse skin after application of 5-aminolevulinic acid. Photodiagn Photodyn Ther 10:538–545.
    OpenUrlCrossRef
  78. ↵
    1. Karu T and
    2. Letokhov V
    (1994) Possible benefits of two-quantum excitation in ALA-PDT? J Photochem Photobiol B 23:261–262.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Kennedy JC,
    2. Pottier RH, and
    3. Pross DC
    (1990) Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 6:143–148.
    OpenUrlCrossRefPubMed
  80. ↵
    1. Kirton SB,
    2. Murray CW,
    3. Verdonk ML, and
    4. Taylor RD
    (2005) Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins. Proteins 58:836–844.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Kobuchi H,
    2. Moriya K,
    3. Ogino T,
    4. Fujita H,
    5. Inoue K,
    6. Shuin T,
    7. Yasuda T,
    8. Utsumi K, and
    9. Utsumi T
    (2012) Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One 7:e50082.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Kolluri S,
    2. Sadlon TJ,
    3. May BK, and
    4. Bonkovsky HL
    (2005) Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem J 392:173–180.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    Komatsu H, Ishii K, Imamura K, Maruyama K, Yonei Y, Masuda H, Tsuchihashi T, and Sajima Y (2000) A case of erythropoietic protoporphyria with liver cirrhosis suggesting a therapeutic value of supplementation with alpha-tocopherol. Hepatol Res 18:298-309.
  84. ↵
    1. Koningsberger JC,
    2. Rademakers LH,
    3. van Hattum J,
    4. de la Faille HB,
    5. Wiegman LJ,
    6. Italiaander E,
    7. van Berge Henegouwen GP, and
    8. Marx JJ
    (1995) Exogenous protoporphyrin inhibits Hep G2 cell proliferation, increases the intracellular hydrogen peroxide concentration and causes ultrastructural alterations. J Hepatol 22:57–65.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Kosenow W
    (1954) Erythrozyten-Primärfluoreszenz bei Porphyrin-Dermatosen. Med Klin 49:1099–1103.
    OpenUrl
  86. ↵
    1. Kosenow W and
    2. Treibs A
    (1953) [Light hypersensitivity and porphyrinemia]. Z Kinderheilkd 73:82–92.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Krishnamurthy P and
    2. Schuetz JD
    (2011) The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival. Curr Pharm Biotechnol 12:647–655.
    OpenUrlCrossRefPubMed
  88. ↵
    1. Krishnamurthy PC,
    2. Du G,
    3. Fukuda Y,
    4. Sun D,
    5. Sampath J,
    6. Mercer KE,
    7. Wang J,
    8. Sosa-Pineda B,
    9. Murti KG, and
    10. Schuetz JD
    (2006) Identification of a mammalian mitochondrial porphyrin transporter. Nature 443:586–589.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Krook G and
    2. Haeger-Aronsen B
    (1982) beta-Carotene in the treatment of erythropoietic protoporphyria: a short review. Acta Derm Venereol Suppl 100:125–129.
    OpenUrlPubMed
  90. ↵
    1. Labbé RF,
    2. Vreman HJ, and
    3. Stevenson DK
    (1999) Zinc protoporphyrin: a metabolite with a mission. Clin Chem 45:2060–2072.
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Langendonk JG,
    2. Balwani M,
    3. Anderson KE,
    4. Bonkovsky HL,
    5. Anstey AV,
    6. Bissell DM,
    7. Bloomer J,
    8. Edwards C,
    9. Neumann NJ,
    10. Parker C,
    11. et al.
    (2015) Afamelanotide for erythropoietic protoporphyria. N Engl J Med 373:48–59.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Lathrop JT and
    2. Timko MP
    (1993) Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science 259:522–525.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    1. Lee RG,
    2. Avner DL, and
    3. Berenson MM
    (1984) Structure-function relationships of protoporphyrin-induced liver injury. Arch Pathol Lab Med 108:744–746.
    OpenUrlPubMed
  94. ↵
    1. Lengweiler S,
    2. Kreim S,
    3. Barman-Aksözen J,
    4. Maurer M, and
    5. Minder EI
    (2015) Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies. Skin Pharmacol Physiol 28:103–113.
    OpenUrlCrossRefPubMed
  95. ↵
    Lewis CA Jr and Wolfenden R (2008) Uroporphyrinogen decarboxylation as a benchmark for the catalytic proficiency of enzymes. Proc Natl Acad Sci USA 105:17328-17333.
  96. ↵
    1. Li F,
    2. Lu J,
    3. Cheng J,
    4. Wang L,
    5. Matsubara T,
    6. Csanaky IL,
    7. Klaassen CD,
    8. Gonzalez FJ, and
    9. Ma X
    (2013) Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 19:418–420.
    OpenUrlCrossRefPubMed
  97. ↵
    1. Lim HW
    (1989) Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 46:671–685.
    OpenUrlPubMed
  98. ↵
    1. Lindblad B,
    2. Lindstedt S, and
    3. Steen G
    (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74:4641–4645.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Ma J,
    2. Xiao S,
    3. An J,
    4. Wang X,
    5. Xu Q,
    6. Dong Y,
    7. Feng Y, and
    8. Wang J
    (2010) A novel splicing mutation and haplotype analysis of the FECH gene in a Chinese family with erythropoietic protoporphyria. J Eur Acad Dermatol Venereol 24:726–729.
    OpenUrlPubMed
  100. ↵
    1. MacCormack MA
    (2008) Photodynamic therapy in dermatology: an update on applications and outcomes. Semin Cutan Med Surg 27:52–62.
    OpenUrlCrossRefPubMed
  101. ↵
    1. Magnus IA,
    2. Jarrett A,
    3. Prankerd TA, and
    4. Rimington C
    (1961) Erythropoietic protoporphyria: a new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 2:448–451.
    OpenUrlPubMed
  102. ↵
    1. Mathews-Roth MM,
    2. Rosner B,
    3. Benfell K, and
    4. Roberts JE
    (1994) A double-blind study of cysteine photoprotection in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 10:244–248.
    OpenUrlPubMed
  103. ↵
    1. McGuire BM,
    2. Bonkovsky HL,
    3. Carithers RL Jr.,
    4. Chung RT,
    5. Goldstein LI,
    6. Lake JR,
    7. Lok AS,
    8. Potter CJ,
    9. Rand E,
    10. Voigt MD,
    11. et al.
    (2005) Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 11:1590–1596.
    OpenUrlCrossRefPubMed
  104. ↵
    1. Meerman L
    (2000) Erythropoietic protoporphyria: an overview with emphasis on the liver. Scand J Gastroenterol Suppl 232:79–85.
    OpenUrlPubMed
  105. ↵
    1. Meerman L,
    2. Haagsma EB,
    3. Gouw AS,
    4. Slooff MJ, and
    5. Jansen PL
    (1999a) Long-term follow-up after liver transplantation for erythropoietic protoporphyria. Eur J Gastroenterol Hepatol 11:431–438.
    OpenUrlCrossRefPubMed
  106. ↵
    1. Meerman L,
    2. Koopen NR,
    3. Bloks V,
    4. Van Goor H,
    5. Havinga R,
    6. Wolthers BG,
    7. Kramer W,
    8. Stengelin S,
    9. Müller M,
    10. Kuipers F,
    11. et al.
    (1999b) Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 117:696–705.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Melefors O,
    2. Goossen B,
    3. Johansson HE,
    4. Stripecke R,
    5. Gray NK, and
    6. Hentze MW
    (1993) Translational control of 5-aminolevulinate synthase mRNA by iron-responsive elements in erythroid cells. J Biol Chem 268:5974–5978.
    OpenUrlAbstract/FREE Full Text
  108. ↵
    1. Meyer-Betz F
    (1913) Untersuchungen über die biologische (photodynamische) Wirkung des Hämatoporphyrins und anderer Derivate des Blut- und Gallenfarbstoffs. Dtsch Arch Klin Med 122:476–503.
    OpenUrl
  109. ↵
    1. Mfouo-Tynga I and
    2. Abrahamse H
    (2015) Cell death pathways and phthalocyanine as an efficient agent for photodynamic cancer therapy. Int J Mol Sci 16:10228–10241.
    OpenUrlCrossRefPubMed
  110. ↵
    1. Minder EI and
    2. Schneider-Yin X
    (2015) Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol 8:43–53.
    OpenUrlCrossRefPubMed
  111. ↵
    1. Minder EI,
    2. Schneider-Yin X,
    3. Steurer J, and
    4. Bachmann LM
    (2009) A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol 55:84–97.
    OpenUrlPubMed
  112. ↵
    1. Mordon S
    (2014) A commentary on the role of skin temperature on the effectiveness of ALA-PDT in dermatology. Photodiagn Photodyn Ther 11:416–419.
    OpenUrlCrossRef
  113. ↵
    1. Mroz P,
    2. Hashmi JT,
    3. Huang YY,
    4. Lange N, and
    5. Hamblin MR
    (2011a) Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol 7:75–91.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Mroz P,
    2. Szokalska A,
    3. Wu MX, and
    4. Hamblin MR
    (2010) Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One 5:e15194.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Mroz P,
    2. Yaroslavsky A,
    3. Kharkwal GB, and
    4. Hamblin MR
    (2011b) Cell death pathways in photodynamic therapy of cancer. Cancers 3:2516–2539.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Munakata H,
    2. Sun JY,
    3. Yoshida K,
    4. Nakatani T,
    5. Honda E,
    6. Hayakawa S,
    7. Furuyama K, and
    8. Hayashi N
    (2004) Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolevulinate synthase. J Biochem 136:233–238.
    OpenUrlAbstract/FREE Full Text
  117. ↵
    1. Napier I,
    2. Ponka P, and
    3. Richardson DR
    (2005) Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 105:1867–1874.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Nelson JC,
    2. Westwood M,
    3. Allen KR,
    4. Newton KE, and
    5. Barth JH
    (1998) The ratio of erythrocyte zinc-protoporphyrin to protoporphyrin IX in disease and its significance in the mechanism of lead toxicity on haem synthesis. Ann Clin Biochem 35:422–426.
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Nestor MS,
    2. Gold MH,
    3. Kauvar AN,
    4. Taub AF,
    5. Geronemus RG,
    6. Ritvo EC,
    7. Goldman MP,
    8. Gilbert DJ,
    9. Richey DF,
    10. Alster TS,
    11. et al.
    (2006) The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol 5:140–154.
    OpenUrlPubMed
  120. ↵
    1. O’Riordan K,
    2. Akilov OE, and
    3. Hasan T
    (2005) The potential for photodynamic therapy in the treatment of localized infections. Photodiagn Photodyn Ther 2:247–262.
    OpenUrlCrossRef
  121. ↵
    1. Oleinick NL and
    2. Evans HH
    (1998) The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 150:S146–S156.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Oustric V,
    2. Manceau H,
    3. Ducamp S,
    4. Soaid R,
    5. Karim Z,
    6. Schmitt C,
    7. Mirmiran A,
    8. Peoc’h K,
    9. Grandchamp B,
    10. Beaumont C,
    11. et al.
    (2014) Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria. Am J Hum Genet 94:611–617.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Paoli M,
    2. Marles-Wright J, and
    3. Smith A
    (2002) Structure-function relationships in heme-proteins. DNA Cell Biol 21:271–280.
    OpenUrlCrossRefPubMed
  124. ↵
    1. Pass HI
    (1993) Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 85:443–456.
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Pastorino JG,
    2. Simbula G,
    3. Gilfor E,
    4. Hoek JB, and
    5. Farber JL
    (1994) Protoporphyrin IX, an endogenous ligand of the peripheral benzodiazepine receptor, potentiates induction of the mitochondrial permeability transition and the killing of cultured hepatocytes by rotenone. J Biol Chem 269:31041–31046.
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Podvinec M,
    2. Handschin C,
    3. Looser R, and
    4. Meyer UA
    (2004) Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci USA 101:9127–9132.
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Poh-Fitzpatrick MB,
    2. Wang X,
    3. Anderson KE,
    4. Bloomer JR,
    5. Bolwell B, and
    6. Lichtin AE
    (2002) Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol 46:861–866.
    OpenUrlCrossRefPubMed
  128. ↵
    1. Proulx KL,
    2. Woodard SI, and
    3. Dailey HA
    (1993) In situ conversion of coproporphyrinogen to heme by murine mitochondria: terminal steps of the heme biosynthetic pathway. Protein Sci 2:1092–1098.
    OpenUrlCrossRefPubMed
  129. ↵
    Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, and Bloomer JR (2006) Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 118:e1896-e1899.
  130. ↵
    1. Rank JM,
    2. Carithers R, and
    3. Bloomer J
    (1993) Evidence for neurological dysfunction in end-stage protoporphyric liver disease. Hepatology 18:1404–1409.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Roberts AG and
    2. Elder GH
    (2001) Alternative splicing and tissue-specific transcription of human and rodent ubiquitous 5-aminolevulinate synthase (ALAS1) genes. Biochim Biophys Acta 1518:95–105.
    OpenUrlPubMed
  132. ↵
    1. Rollakanti KR,
    2. Kanick SC,
    3. Davis SC,
    4. Pogue BW, and
    5. Maytin EV
    (2013) Techniques for fluorescence detection of protoporphyrin IX in skin cancers associated with photodynamic therapy. Photonics Lasers Med 2:287–303.
    OpenUrlPubMed
  133. ↵
    1. Rouault TA and
    2. Tong WH
    (2005) Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 6:345–351.
    OpenUrlCrossRefPubMed
  134. ↵
    1. Sadlon TJ,
    2. Dell’Oso T,
    3. Surinya KH, and
    4. May BK
    (1999) Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. Int J Biochem Cell Biol 31:1153–1167.
    OpenUrlCrossRefPubMed
  135. ↵
    1. Samuel D,
    2. Boboc B,
    3. Bernuau J,
    4. Bismuth H, and
    5. Benhamou JP
    (1988) Liver transplantation for protoporphyria: evidence for the predominant role of the erythropoietic tissue in protoporphyrin overproduction. Gastroenterology 95:816–819.
    OpenUrlPubMed
  136. ↵
    1. Sassa S and
    2. Granick S
    (1970) Induction of -aminolevulinic acid synthetase in chick embryo liver cells in cluture. Proc Natl Acad Sci USA 67:517–522.
    OpenUrlAbstract/FREE Full Text
  137. ↵
    1. Sawyer TK,
    2. Sanfilippo PJ,
    3. Hruby VJ,
    4. Engel MH,
    5. Heward CB,
    6. Burnett JB, and
    7. Hadley ME
    (1980) 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 77:5754–5758.
    OpenUrlAbstract/FREE Full Text
  138. ↵
    1. Scassa ME,
    2. Varone CL,
    3. Montero L, and
    4. Cánepa ET
    (1998) Insulin inhibits delta-aminolevulinate synthase gene expression in rat hepatocytes and human hepatoma cells. Exp Cell Res 244:460–469.
    OpenUrlCrossRefPubMed
  139. ↵
    Schauder A, Avital A, and Malik Z (2010) Regulation and gene expression of heme synthesis under heavy metal exposure–review. J Environ Pathol Toxicol Oncol 29:137-158.
  140. ↵
    1. Schwartz S,
    2. Raux WA,
    3. Schacter BA,
    4. Stephenson BD, and
    5. Shoffner RN
    (1980) Loss of hereditary uterine protoporphyria through chromosomal rearrangement in mutant Rhode Island red hens. Int J Biochem 12:935–940.
    OpenUrlCrossRefPubMed
  141. ↵
    1. Shaw GC,
    2. Cope JJ,
    3. Li L,
    4. Corson K,
    5. Hersey C,
    6. Ackermann GE,
    7. Gwynn B,
    8. Lambert AJ,
    9. Wingert RA,
    10. Traver D,
    11. et al.
    (2006) Mitoferrin is essential for erythroid iron assimilation. Nature 440:96–100.
    OpenUrlCrossRefPubMed
  142. ↵
    1. Shimizu Y,
    2. Ida S,
    3. Naruto H, and
    4. Urata G
    (1978) Excretion of porphyrins in urine and bile after the administration of delta-aminolevulinic acid. J Lab Clin Med 92:795–802.
    OpenUrlPubMed
  143. ↵
    1. Sinclair PR,
    2. Gorman N,
    3. Walton HS,
    4. Sinclair JF,
    5. Jacobs JM, and
    6. Jacobs NJ
    (1994) Protoporphyrinogen accumulation in cultured hepatocytes treated with the diphenyl ether herbicide, acifluorfen. Cell Mol Biol 40:891–897.
    OpenUrlPubMed
  144. ↵
    1. Singal AK,
    2. Parker C,
    3. Bowden C,
    4. Thapar M,
    5. Liu L, and
    6. McGuire BM
    (2014) Liver transplantation in the management of porphyria. Hepatology 60:1082–1089.
    OpenUrlCrossRefPubMed
  145. ↵
    1. Smith KM
    (1979) Protoporphyrin IX: some recent research. Acc Chem Res 12:374–381.
    OpenUrlCrossRef
  146. ↵
    1. Smith LJ,
    2. Kahraman A, and
    3. Thornton JM
    (2010) Heme proteins--diversity in structural characteristics, function, and folding. Proteins 78:2349–2368.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Smith SJ and
    2. Cox TM
    (1997) Translational control of erythroid delta-aminolevulinate synthase in immature human erythroid cells by heme. Cell Mol Biol 43:103–114.
    OpenUrlPubMed
  148. ↵
    1. Solazzo M,
    2. Fantappiè O,
    3. D’Amico M,
    4. Sassoli C,
    5. Tani A,
    6. Cipriani G,
    7. Bogani C,
    8. Formigli L, and
    9. Mazzanti R
    (2009) Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 69:7235–7242.
    OpenUrlAbstract/FREE Full Text
  149. ↵
    1. Szechciński J,
    2. Skoczyńska A, and
    3. Andreasik Z
    (1986) [Liver cirrhosis in congenital erythropoietic protoporphyria]. Pol Tyg Lek 41:899–901.
    OpenUrlPubMed
  150. ↵
    1. Taketani S,
    2. Kohno H,
    3. Okuda M,
    4. Furukawa T, and
    5. Tokunaga R
    (1994) Induction of peripheral-type benzodiazepine receptors during differentiation of mouse erythroleukemia cells: a possible involvement of these receptors in heme biosynthesis. J Biol Chem 269:7527–7531.
    OpenUrlAbstract/FREE Full Text
  151. ↵
    1. Thapar M and
    2. Bonkovsky HL
    (2008) The diagnosis and management of erythropoietic protoporphyria. Gastroenterol Hepatol 4:561–566.
    OpenUrl
  152. ↵
    1. Tian Q,
    2. Li T,
    3. Hou W,
    4. Zheng J,
    5. Schrum LW, and
    6. Bonkovsky HL
    (2011) Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells. J Biol Chem 286:26424–26430.
    OpenUrlAbstract/FREE Full Text
  153. ↵
    1. Tintle S,
    2. Alikhan A,
    3. Horner ME,
    4. Hand JL, and
    5. Davis DM
    (2014) Cutaneous porphyrias part II: treatment strategies. Int J Dermatol 53:3–24.
    OpenUrlCrossRefPubMed
  154. ↵
    1. Todd DJ
    (1991) Gallstones in children. Am J Dis Child 145:971–972.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Troadec MB,
    2. Warner D,
    3. Wallace J,
    4. Thomas K,
    5. Spangrude GJ,
    6. Phillips J,
    7. Khalimonchuk O,
    8. Paw BH,
    9. Ward DM, and
    10. Kaplan J
    (2011) Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria. Blood 117:5494–5502.
    OpenUrlAbstract/FREE Full Text
  156. ↵
    1. Van Hattum J,
    2. Baart de la Faille H,
    3. Van den Berg JW,
    4. Edixhoven-Bosdijk A, and
    5. Wilson JH
    (1986) Chenodeoxycholic acid therapy in erythrohepatic protoporphyria. J Hepatol 3:407–412.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Varone CL,
    2. Giono LE,
    3. Ochoa A,
    4. Zakin MM, and
    5. Cánepa ET
    (1999) Transcriptional regulation of 5-aminolevulinate synthase by phenobarbital and cAMP-dependent protein kinase. Arch Biochem Biophys 372:261–270.
    OpenUrlCrossRefPubMed
  158. ↵
    1. Wahlin S,
    2. Floderus Y,
    3. Stål P, and
    4. Harper P
    (2011a) Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 269:278–288.
    OpenUrlCrossRefPubMed
  159. ↵
    1. Wahlin S and
    2. Harper P
    (2010) The role for BMT in erythropoietic protoporphyria. Bone Marrow Transplant 45:393–394.
    OpenUrlCrossRefPubMed
  160. ↵
    1. Wahlin S,
    2. Stal P,
    3. Adam R,
    4. Karam V,
    5. Porte R,
    6. Seehofer D,
    7. Gunson BK,
    8. Hillingsø J,
    9. Klempnauer JL,
    10. Schmidt J,
    11. et al., and
    12. European Liver and Intestine Transplant Association
    (2011b) Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transpl 17:1021–1026.
    OpenUrlPubMed
  161. ↵
    1. Warren LJ and
    2. George S
    (1998) Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB phototherapy. Australas J Dermatol 39:179–182.
    OpenUrlCrossRefPubMed
  162. ↵
    1. Wendler G,
    2. Lindemann P,
    3. Lacapère JJ, and
    4. Papadopoulos V
    (2003) Protoporphyrin IX binding and transport by recombinant mouse PBR. Biochem Biophys Res Commun 311:847–852.
    OpenUrlCrossRefPubMed
  163. ↵
    1. Whatley SD,
    2. Ducamp S,
    3. Gouya L,
    4. Grandchamp B,
    5. Beaumont C,
    6. Badminton MN,
    7. Elder GH,
    8. Holme SA,
    9. Anstey AV,
    10. Parker M,
    11. et al.
    (2008) C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83:408–414.
    OpenUrlCrossRefPubMed
  164. ↵
    1. Whitcombe DM,
    2. Carter NP,
    3. Albertson DG,
    4. Smith SJ,
    5. Rhodes DA, and
    6. Cox TM
    (1991) Assignment of the human ferrochelatase gene (FECH) and a locus for protoporphyria to chromosome 18q22. Genomics 11:1152–1154.
    OpenUrlCrossRefPubMed
  165. ↵
    1. Wingert RA,
    2. Galloway JL,
    3. Barut B,
    4. Foott H,
    5. Fraenkel P,
    6. Axe JL,
    7. Weber GJ,
    8. Dooley K,
    9. Davidson AJ,
    10. Schmid B,
    11. et al., and
    12. Tübingen 2000 Screen Consortium
    (2005) Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 436:1035–1039.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Wu N,
    2. Yin L,
    3. Hanniman EA,
    4. Joshi S, and
    5. Lazar MA
    (2009) Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbalpha. Genes Dev 23:2201–2209.
    OpenUrlAbstract/FREE Full Text
  167. ↵
    1. Wu Z,
    2. Puigserver P,
    3. Andersson U,
    4. Zhang C,
    5. Adelmant G,
    6. Mootha V,
    7. Troy A,
    8. Cinti S,
    9. Lowell B,
    10. Scarpulla RC,
    11. et al.
    (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Yamamoto M,
    2. Arimura H,
    3. Fukushige T,
    4. Minami K,
    5. Nishizawa Y,
    6. Tanimoto A,
    7. Kanekura T,
    8. Nakagawa M,
    9. Akiyama S, and
    10. Furukawa T
    (2014) Abcb10 role in heme biosynthesis in vivo: Abcb10 knockout in mice causes anemia with protoporphyrin IX and iron accumulation. Mol Cell Biol 34:1077–1084.
    OpenUrlAbstract/FREE Full Text
  169. ↵
    1. Zheng J,
    2. Shan Y,
    3. Lambrecht RW,
    4. Donohue SE, and
    5. Bonkovsky HL
    (2008) Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Mol Cell Biochem 319:153–161.
    OpenUrlCrossRefPubMed
  170. ↵
    1. Zhou S,
    2. Zong Y,
    3. Ney PA,
    4. Nair G,
    5. Stewart CF, and
    6. Sorrentino BP
    (2005) Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105:2571–2576.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 356 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 356, Issue 2
1 Feb 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Protoporphyrin IX: the Good, the Bad, and the Ugly
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMinireview

Pharmacology and Toxicology of PPIX

Madhav Sachar, Karl E. Anderson and Xiaochao Ma
Journal of Pharmacology and Experimental Therapeutics February 1, 2016, 356 (2) 267-275; DOI: https://doi.org/10.1124/jpet.115.228130

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleMinireview

Pharmacology and Toxicology of PPIX

Madhav Sachar, Karl E. Anderson and Xiaochao Ma
Journal of Pharmacology and Experimental Therapeutics February 1, 2016, 356 (2) 267-275; DOI: https://doi.org/10.1124/jpet.115.228130
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • PPIX Biosynthesis
    • Regulation of PPIX Biosynthesis through ALAS
    • Disregulation of PPIX Homeostasis
    • Clinical Manifestations and Management of PPIX Toxicity
    • PPIX-Based Strategies for Diagnosis and Therapy
    • Conclusions
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Phytochemicals treat IBD and colon cancer
  • Biomarker-Centric Approach to Drug Development
  • Smoking Could Worsen COVID-19 Outcome
Show more Minireview

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics